An open-label trial of memantine for cognitive impairment in patients with posttraumatic stress disorder

Sriram Ramaswamy, Jayakrishna Madabushi, John Hunziker, Subhash C. Bhatia, Frederick Petty

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

Background. Studies using standard neuropsychological instruments have demonstrated memory deficits in patients with PTSD. We evaluated the efficacy and safety of the N-methyl-D-aspartate antagonist memantine in veterans with PTSD and cognitive impairment. Methods. Twenty-six veterans with PTSD and cognitive impairment received 16 weeks of memantine in an open-label fashion. Cognition was assessed using the Spatial Span, Logical Memory I, and Letter-Number Sequencing subtests of the Wechsler Memory Scale III and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). RBANS measures attention, language, visuospatial skills, and immediate and delayed memories. The Clinician Administered PTSD Scale (CAPS), Hamilton Depression Scale (HAM-D), Hamilton Anxiety Scale (HAM-A), Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), and Sheehan Disability Scale (SDS) were secondary outcome measures. Results. There was a significant improvement in RBANS, both total and subscale scores (P

Original languageEnglish (US)
Article number934162
JournalJournal of Aging Research
Volume2015
DOIs
StatePublished - 2015

All Science Journal Classification (ASJC) codes

  • Geriatrics and Gerontology

Fingerprint Dive into the research topics of 'An open-label trial of memantine for cognitive impairment in patients with posttraumatic stress disorder'. Together they form a unique fingerprint.

  • Cite this